Tag Archives: Roche
By Clark Herman | Published: August 7, 2013
Roche this week has announced a partnership with the UN-backed Medicines Patent Pool (MPP) to provide its drug valganciclovir, better known in the developed world as Valcyte, in 138 countries for a reduced price. In addition to making the drug available in these markets for up to 90% cheaper than current price, Roche has decided [...]
By Clark Herman | Published: August 5, 2013
With announcements pouring in since the beginning of this year, FDA’s fourth and newest expedited approval pathway for medicines has begun to bear fruit. Established in 2012 within the FDA Safety and Innovation Act (FDASIA), Breakthrough Therapy designations have so far totaled 25 as of the end of July. With a separate senior management team [...]
By Ben Comer | Published: November 16, 2012
Given the amount of activity in the hepatitis C drug development space – as evidenced in PharmExec’s 2013 Pipeline report – patients are scouring the internet for information on the disease, available treatments, and soon to be available treatments. A new Industry Standard Research report examines the digital cracks consumers encounter when looking for [...]
By Guest Blogger | Published: September 21, 2012
By Amy Ritter. Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.
By Ben Comer | Published: May 7, 2012
The news that Roche scrapped development on its CETP inhibitor dalcetrapib, a drug designed to raise HDL cholesterol in the blood, likely presages the shuttering of Lilly’s development program for its CETP inhibitor, evacetrapib, industry experts and analysts say.